JMSS and Xincere Attended BIO KOREA 2025 

출처 : JMSS  2025.05.12 11:26

Seoul, South Korea – May 7-9, 2025 — Jin Medical Science Service (JMSS), a leading clinical development and medical consulting company, participated in BIO KOREA 2025 alongside its strategic China-based partner, Xincere, marking a significant step forward in expanding regional collaboration and global outreach.

During the event, JMSS and Xincere held more than a dozen high-level meetings with prominent Korean biotechnology firms, including Dr. Noah, CEFO, CONNEXT, Medipost, Olix, Epibiotech, YiPSCELL, RudaCure, and Inventage. Discussions centered on potential licensing-out opportunities for novel biomedicines currently in Phase I–III clinical trials.

In addition to business development efforts, JMSS is actively enhancing its IT infrastructure to support its growing needs in due diligence analysis and clinical data management. As part of this digital transformation initiative, the team met with JNPMEDI, a leading Korean CRO and digital health solutions provider, to explore collaborative opportunities in technology integration.

JMSS and Xincere were honored to attend the official BIO KOREA 2025 Reception, hosted by the Korea Health Industry Development Institute (KHIDI)—a reflection of their growing recognition and integration within the Korean biotech ecosystem. During the event, they also engaged in discussions with KHIDI on potential collaboration to support the successful licensing-out of Korean biotechnologies into Chinese pharma industry.

Following the conference, the delegation continued its engagement with site visits to Seoul National University Hospital (SNUH) and Inje University Hospital, where they held in-depth academic discussions with two of Korea’s leading clinical pharmacologists: Professor Kyung-Sang Yu and Professor Jae-Gook Shin. These interactions further strengthened ties with key opinion leaders (KOLs) in clinical research and pharmacology.

The successful participation at BIO KOREA 2025 underscores JMSS’s ongoing mission to build a dynamic international network, advance technical capabilities, and support the cross-border licensing and development of innovative biopharmaceuticals.